Paul MacLeman has over 25 years’ experience across all phases of the life sciences sector. With a career-spanning veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance, Paul has expertise in capital raising, business development, technology commercialisation, and sales and marketing globally. Paul has launched products using both in-house and outsourced sales staff in Australia and the US. He has founded life sciences start-ups in the biologics area and worked in investment banking, focusing on the analysis and financing of technology companies. Paul has previously served as Chairman, Director or Managing Director/CEO of several VC funded ASX, NASDAQ, CSE and TSX listed companies. Paul is currently Executive Chairman of Isla Pharmaceuticals Inc. and Chairman of AdAlta Limited (1AD:ASX).
Paul is currently Executive Chairman of Isla Pharmaceuticals Inc. and Chairman of AdAlta Limited (1AD:ASX). Paul chairs the Industry Review Committee for the Pharmaceutical Manufacturing National Training Package for the AISC. He is an expert advisor to PharmaVentures (Oxford, UK) and Mind Medicine. Paul also serves on a number of other not-for-profit and government advisory groups and has recently provided advice to both the Department of Education, Skills and Employment (DESE) and the Department of Industry, Science, Energy and Resources (DISER) related to COVID-19.
Dr. Brian Richardson has more than 40 years’ experience in the pharmaceutical industry, including many senior leadership positions such as Global Head of Musculoskeletal Disease Therapeutic Area at Novartis Institutes for Biomedical Research; Deputy Head of Preclinical Drug Safety, Head of Pathology and Experimental Toxicology, Head of Immunology, Inflammation and Respiratory Research, as well as Senior Project Manager for the worldwide development of all new therapies for metabolic, cardiovascular and respiratory diseases for Sandoz Pharma. He was Head of Preclinical Research in Switzerland and UK at the time of the merger of Sandoz with Ciba and played a key role in the integration of their of the research organisations, which resulted in The Novartis Institutes for Biomedical Research. He was subsequently appointed Global Head of the Arthritis and Bone Metabolism Therapeutic Area and also directed discovery and development efforts in gastrointestinal and muscle diseases. Dr. Richardson’s laboratories led the discovery, development and introduction of several new therapies including Navoban, Simulect, Ilaris, Certican, Gilenya and Cosentyx. He has published more than 60 original peer-reviewed papers and contributed many book chapters in the fields of pathophysiology, endocrinology and receptor pharmacology.
Liddy McCall has over 25 years of experience in senior Board and management roles. She is co-founder of three biotechnology companies, successfully achieving three FDA drug registrations and one FDA/CE Mark medical device approval. She is an inventor on patents granted in major jurisdictions translating novel G-protein coupled pharmacology into a therapeutic drug treatment now in mulitple Phase 3 clinical trials with Dimerix Limited (ASX:DXB). Liddy co-founded IIF venture capital fund, Yuuwa Capital LP, which is responsible for a portfolio of six companies commercialising biotechnology and IT innovation. She was a founder of the iCeutica Inc Group (acquired in 2011 with significant value created for shareholders). Liddy was an Associate Director in the Corporate Advisory Group of Macquarie Bank and prior to that worked as a lawyer with a leading Australian law firm.
Liddy is on the Board of not-for-profit Ear Science Institute Australia, is a committee member of the Australian Government Biomedical Translation Fund, and is also a Non-Executive Director of Adalta Limited (1AD:ASX), Argenica Therapeutics Limited, Agworld Pty Ltd, Nexgen Plants Pty Ltd and The Tailor Made Spirits Company Limited.
Mr. Eran Gilboa has served as CFO for numerous global public and private companies in the fields of technology, real estate, finance and media. Eran has also been involved in founding several start-up companies based on in-license technologies from universities, including medical companies such as NeuroCords Ltd, SuperTrans Medical Ltd and Curatio.DL Ltd. Eran has strong experience building start-up companies and leading them to commercialisation, including hiring the appropriate management teams, raising capital, taking companies public and assisting management in all activities.
Eran holds a Chartered Professional Accountant license, a B.A. degree in Economics and Management, with a specialty in Finance, from the College of Management in Israel and an LLM from Bar Ilan University.
Dr. Irit Arbel brings significant senior multidisciplinary biopharma experience to SuperTrans Medical. Dr Arbel is currently the Vice Chairman of Brainstorm Cell Therapeutics Inc. (Nasdaq:BCLI) and is on the Board of IsraCann, Israel’s first pure-play cannabis firm. She is a Co-Founder and served as CEO of Neurocords Ltd., a company focused on developing new treatments for peripheral and spinal cord regeneration; and served as Executive Vice President of Research and Development at Savicell Diagnostics, a biomedical company. Dr. Arbel previously served as Chairperson of Real Aesthetics, a company specialising in cellulite ultrasound treatment, and BRH Medical, a developer of medical devices for wound healing. She was also Director of M&A at RFB Investment House, a private investment firm focusing on early-stage technology-related companies. Previously, Dr. Arbel was President and CEO of Pluristem Therapeutics Inc. (Nasdaq: PSTI), a biotechnology company, and prior to that, Israeli Sales Manager of Merck, Sharp & Dohme, a pharmaceutical company.
Dr. Arbel earned her PhD in 1997 in Neurobiology, after performing research in the area of multiple sclerosis.
Having trained in the UK, Israel and the USA, Dr. Lewis Neville brings significant expertise in all phases of R&D of drug therapeutics, particularly in the bacterial infectious disease arena. In addition, Dr. Neville has strong management experience in biotech companies. He founded and resided on the Board of Lostam Biopharmaceuticals (Israel), an early-stage infectious disease drug company delivering novel monoclonal antibodies for the targeting Gram-negative bacteria (Pseudomonas aeruginosa). Following this, he managed Zolex Therapeutics (Israel) in the development of small molecular weight antibiotics targeting Gram-positive bacteria (Methicillin-resistant Staphylococcus aureus).
Dr. Neville gained his PhD at the University of Southampton, U.K. He previously held two post-doctoral positions at the Hebrew University of Jerusalem and University of Pennsylvania following a Research Assistant Professor academic post at Jefferson Medical College, Thomas Jefferson University from 1991-1996.
Dr. Jacob Rendell is an R&D Executive with over 13 years' experience in the pharmaceutical industry. Jacob directed the Lifecycle management portfolio of global R&D in Teva's API division, and led interdisciplinary and multinational R&D teams in API process development from laboratory scale to cost-efficient GMP production, with an emphasis on small molecules and peptide development. His expertise includes pharmaceutical development strategy, intellectual property value creation, regulatory affairs, risk and project management. He also conducted medicinal chemistry research in hepatitis C for GSK, UK.
Jacob gained a PhD in Organic Chemistry from Imperial College London following a 1st class honours Master’s degree in Chemistry at UMIST, Manchester UK. He recently completed his studies for an MBA, with a focus on Biomedical Entrepreneurship from the Hebrew University of Jerusalem. Jacob is the author of numerous peer-reviewed scientific articles and patents with antibiotic, antiviral, gastrointestinal and oncology applications.
Extensive experience as a corporate advisor in the pharmaceutical / biotech industry successfully executing transactions in all major capital markets. Previously acted as Non-executive Director and CEO for an ASX-listed company and early-stage venture funded businesses, as well as a CEO of a deep tech venture fund. Previous roles include over 25+ years corporate finance and management consulting experience including with Morgan Stanley’s Healthcare team in New York and London covering clients in the pharmaceutical and emerging European biotechnology market and Deutsche Bank AG in Melbourne covering general industries in health and energy. During this period, Andrew was instrumental in completing a number of landmark transaction in each jurisdiction. Andrew has a PhD in biotechnology focusing on gene regulation in the context of seasonal asthma and hayfever and an MBA from the University of Melbourne.
Cameron is the Managing Director of Bio101, a financial services firm providing accounting, tax and company secretarial services specialising in the healthcare and life science sectors. A qualified Chartered Accountant, Cameron acts as CFO and Company Secretary for a number of ASX listed life science companies and Venture Capital investee companies. In his role at Bio101 Cameron has assisted clients in the IPO process and fills the role and acts as Australian Resident Director.
Cameron is a Director and Treasurer of registered charities Cystic Fibrosis Community Care Ltd and BioAutism Ltd.
